Zoetis Inc. 2025 Annual Report (10-K) Summary
Business Context and Reporting Period
This summary covers the Form 10-K for Zoetis Inc. for the fiscal year ended December 31, 2025. Zoetis is a global leader in the animal health industry, focused on the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products, and services for companion animals (dogs, cats, horses) and livestock (cattle, swine, poultry, fish, sheep). The company operates through two geographic segments: United States and International.
Key Financial Metrics
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Total Revenue | $9,467 million | $9,256 million | +2% |
| Net Income (GAAP) | $2,673 million | $2,486 million | +8% |
| Adjusted Net Income | $2,847 million | $2,693 million | +6% |
| Diluted EPS (GAAP) | $6.02 | $5.47 | +10% |
| Operating Cash Flow | $2,904 million | $2,953 million | -2% |
| Cost of Sales Margin | 28.2% | 29.4% | -1.2 pts |
| Total Debt Outstanding | $9.15 billion | $6.65 billion | +38% |
| Cash and Equivalents | $2,312 million | $1,987 million | +16% |
Segment Performance: U.S. revenue was $5,097 million (flat vs. 2024), while International revenue was $4,254 million (+4%). Companion animal products accounted for approximately 70% of total revenue, while livestock products accounted for 29%.
Material Changes vs. Prior Period
- Revenue Growth Drivers: Operational revenue growth of 3% was driven by price growth (~4%) and volume growth from key franchises (Simparica, Apoquel, Cytopoint, Librela). This was partially offset by a ~3% volume decrease due to the divestiture of the medicated feed additive (MFA) portfolio in late 2024.
- Foreign Exchange Impact: Foreign exchange rates negatively impacted reported revenue growth by approximately 1% ($36 million).
- Debt Structure: Total debt increased significantly due to the issuance of $2.0 billion in 0.250% Convertible Senior Notes (due 2029) and $1.85 billion in new Senior Notes (due 2028 and 2035) in August 2025. Proceeds were used to redeem $1.35 billion of maturing debt and fund share repurchases.
- Share Repurchases: The company repurchased 23.9 million shares for $3.2 billion in 2025. As of year-end, $2.4 billion remained under the $6 billion authorization.
- Acquisitions: Acquired Veterinary Pathology Group (U.K./Ireland) in 2025. Acquisitions of PetMedix and adivo were completed in 2023.
Guidance, Outlook, and Risks
Management Commentary: Management expects to eliminate the one-month reporting lag for international subsidiaries in 2026, aligning all fiscal years to December 31. This change resulted in an acceleration of sales into Q4 2025 (approx. 2.5% to 3.5% increase in International Q4 sales) which is not expected to recur in Q4 2026.
Key Risks and Contingencies:
- Patent Expirations: Patents for key products like Draxxin and Excede/Naxcel have expired in major markets, leading to generic competition and sales declines (e.g., Draxxin U.S. sales down 66% since 2021).
- Regulatory & Tax: The company is under IRS audit for tax years 2017-2018 regarding the one-time mandatory deemed repatriation tax. The IRS proposed an additional liability of approximately $450 million; Zoetis disagrees and is defending its position.
- Supply Chain & Manufacturing: Risks include capacity imbalances, reliance on third-party contract manufacturers (over 90 CMOs), and potential disruptions from weather or geopolitical events.
- Antibiotic Restrictions: Increasing global restrictions on antibacterials in food-producing animals could impact the $713 million revenue stream from livestock antibacterials.
Investor Verification Checklist
- Debt Servicing: Verify the company's ability to service the increased debt load ($9.15 billion) given the mix of fixed and variable rates and upcoming maturities.
- Generic Competition: Monitor sales trends for top-selling products (Simparica, Apoquel, Librela) as they face potential patent cliffs and generic entry.
- IRS Dispute: Track the resolution of the IRS audit regarding the 2018 repatriation tax, as a loss could materially impact future tax provisions.
- Fiscal Year Alignment: Confirm the impact of the 2026 fiscal year alignment on Q4 2026 comparability, as the Q4 2025 sales acceleration will not repeat.
- Product Pipeline: Assess the commercial success of new approvals in 2025 (e.g., Lenivia, Portela, Dectomax-CA1) to offset legacy product declines.